VAGIFEM Drug Patent Profile

When do Vagifem patents expire, and what generic alternatives are available?

Vagifem is a drug marketed by Novo Nordisk Inc and is included in one NDA.

The generic ingredient in VAGIFEM is estradiol. There are seventy-five drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the estradiol profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Vagifem

A generic version of VAGIFEM was approved as estradiol by BARR LABS INC on October 22^nd, 1997.

Summary for VAGIFEM

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	17
Patent Applications:	3,865
Drug Prices:	Drug price information for VAGIFEM
Drug Sales Revenues:	Drug sales revenues for VAGIFEM
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VAGIFEM
What excipients (inactive ingredients) are in VAGIFEM?	VAGIFEM excipients list
DailyMed Link:	VAGIFEM at DailyMed

See drug prices for VAGIFEM

See drug sales revenues for VAGIFEM

Recent Clinical Trials for VAGIFEM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Breast Cancer Research Foundation	Phase 2
University of Washington	Phase 2
University of California, Irvine	PHASE4

See all VAGIFEM clinical trials

Pharmacology for VAGIFEM

Drug Class	Estrogen
Mechanism of Action	Estrogen Receptor Agonists

Paragraph IV (Patent) Challenges for VAGIFEM

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VAGIFEM	Vaginal Tablets	estradiol	10 mcg	020908	1	2013-01-02

US Patents and Regulatory Information for VAGIFEM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-002	Nov 25, 2009	AB	RX	Yes	Yes
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-001	Mar 26, 1999		DISCN	Yes	No

Expired US Patents for VAGIFEM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-002	Nov 25, 2009	5,860,946
Novo Nordisk Inc	VAGIFEM	estradiol	TABLET;VAGINAL	020908-002	Nov 25, 2009	7,018,992

International Patents for VAGIFEM

See the table below for patents covering VAGIFEM around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2004515531
Australia	3254397
World Intellectual Property Organization (WIPO)	9801180
World Intellectual Property Organization (WIPO)	0247692
Canada	2258310	INSTRUMENT POUR L'INTRODUCTION D'UN SUPPOSITOIRE (INSTRUMENT FOR INSERTING A SUPPOSITORY)
Germany	10179223

Supplementary Protection Certificates for VAGIFEM

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0398460	04C0022	France		PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
1453521	CA 2016 00016	Denmark		PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
2782584	301153	Netherlands		PRODUCT NAME: COMPOSITION CONTAINING BOTH ESTRADIOL (17SS-ESTRADIOL), OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF (INCLUDING IN HEMIHYDRATE FORM), AND PROGESTERONE; NATIONAL REGISTRATION NO/DATE: RVG 125821 20210611; FIRST REGISTRATION: BE BE582231 20210406
0136011	2000C/027	Belgium		PRODUCT NAME: ETHINYLESTRADIOLUM / NORETHISTERONI ACETAS; NAT. REGISTRATION NO/DATE: 19 IS 106 F3 20000911; FIRST REGISTRATION: NL RVG 23909 19991124
1214076	49/2008	Austria		PRODUCT NAME: WIRKSTOFFKOMBINATION VON ETHINYLESTRADIOL UND DROSPIRENON; REGISTRATION NO/DATE: 1-27586 20080612
0285237	95C0008	Belgium		PRODUCT NAME: ESTRADIOL, HEMIHYDRATE; NAT. REGISTRATION NO/DATE: NL 19489 19941107; FIRST REGISTRATION: FR - NL 19489 19941107

Market Dynamics and Financial Trajectory for VAGIFEM

Last updated: July 27, 2025

Introduction

VAGIFEM, a vaginal estrogen capsule primarily used to manage menopausal vaginal atrophy, holds a distinctive position within the broader hormone replacement therapy (HRT) segment. As the global population ages, with an increasing prevalence of menopause-related conditions, the market relevance and financial prospects for VAGIFEM are poised for significant shifts. This analysis explores the market dynamics influencing VAGIFEM's trajectory, referencing current trends, regulatory environments, competitive landscape, and economic factors.

---

Market Overview and Demand Drivers

The rising global burden of menopause-associated genitourinary syndromes has catalyzed increased utilization of localized estrogen therapies such as VAGIFEM. According to data from the North American Menopause Society, approximately 50% of menopausal women experience vaginal atrophy symptoms, including dryness, irritation, and dyspareunia [1]. These issues impair quality of life and drive demand for targeted hormonal treatments.

Furthermore, the aging demographic plays a pivotal role. The United Nations projects that by 2050, women aged 60 and above will constitute over 20% of the global population, intensifying demand for women’s health products [2]. The preference for minimally invasive, localized therapies over systemic hormone therapies, owing to safety profiles, further boosts the appeal of vaginal estrogen formulations like VAGIFEM.

Market Dynamics and Competitive Environment

VAGIFEM faces competition from both oral and other topical estrogen products, including Estrace, Premarin, and generic vaginal estrogen therapies. Its unique positioning as a capsule offers advantages such as ease of administration and targeted delivery, which align with patient preferences and compliance trends.

However, patent expiry, especially in markets like the US and Europe, introduces significant competitive pressure. Generic formulations and biosimilars are expected to enter the market, exerting downward pricing pressures and eroding profit margins. The entry of these alternatives is reinforced by regulatory pathways encouraging biosimilar and generic development, potentially diluting VAGIFEM's market share.

The clinical landscape is also shaped by emerging non-hormonal treatments and alternative modalities for vaginal atrophy, such as laser therapies and moisturizers, offering additional competition. Nevertheless, the established efficacy and familiarity of hormonal therapies sustain their demand, underpinning VAGIFEM’s market positioning.

Regulatory and Reimbursement Environment

Regulatory considerations significantly influence VAGIFEM’s commercial trajectory. US Food and Drug Administration (FDA) approval status, along with European Medicines Agency (EMA) assessments, directly impact market accessibility and acceptance.

Reimbursement frameworks augment market penetration. In healthcare systems with comprehensive coverage, patients are more likely to opt for VAGIFEM, particularly as outpatient, prescription-based treatments. Conversely, high out-of-pocket costs can constrain demand, especially in markets with limited insurance coverage for hormonal therapies.

Recent regulatory emphasis on safety, especially concerning estrogen-related risks, has prompted additional clinical studies and post-marketing surveillance. These steps, while essential, can prolong approval timelines and increase costs, impacting financial forecasting.

Pricing Strategies and Revenue Potential

Pricing management is crucial. VAGIFEM is positioned as a premium product, justified by its delivery mechanism, efficacy, and safety profile. However, competitive pressures and the introduction of generics necessitate strategic pricing to sustain profitability.

Assuming successful market entry and sustained demand, revenue projections in mature markets could reach hundreds of millions USD annually. The global market for vaginal estrogen products is forecasted to grow at a Compound Annual Growth Rate (CAGR) of approximately 6-8% over the next five years, driven by demographic trends and increasing awareness [3].

Financial Trajectory: Opportunities and Challenges

Opportunities:

• Market Expansion: Targeting emerging markets with increasing healthcare infrastructure, such as Asia-Pacific and Latin America, offers substantial revenue expansion.
• Product Line Diversification: Developing combination therapies (e.g., estrogen plus progesterone) or novel delivery systems can enhance market share.
• Partnerships and Licensing: Collaborations with regional pharmaceutical companies can facilitate broader distribution, especially where regulatory pathways favor local partnerships.

Challenges:

• Pricing Pressures: The entrance of generics and biosimilars will likely result in decreasing per-unit margins.
• Regulatory Delays: Lengthy approval processes in certain jurisdictions may postpone revenue realization.
• Safety Concerns: Evolving safety profiles and regulatory warnings can influence prescribing behaviors, impacting sales volume.

Emerging Trends Impacting Market Trajectory

• Patient-Centric Care: Increasing demand for minimally invasive, localized treatments favor products like VAGIFEM.
• Digital Health Initiatives: Telemedicine platforms facilitate improved access and patient education, potentially expanding demand.
• Regulatory Focus on Safety: Heightened scrutiny over hormone therapy-associated risks may influence prescribing practices and market dynamics.

Strategic Outlook

The financial prospects for VAGIFEM are favorable if manufacturers effectively leverage demographic trends, ensure regulatory compliance, and adapt to competitive pressures. Emphasizing clinical benefits, safety profiles, and patient convenience will be vital in maintaining market share and revenue streams.

Continued investment in clinical research and partnerships can foster innovation, sustaining VAGIFEM’s market relevance amidst a dynamic landscape. Cost-effective manufacturing and strategic regulatory navigation will be essential to maximize profitability, especially in the face of intensified generic competition.

---

Key Takeaways

• The aging female demographic globally underpins sustained demand for vaginal estrogen therapies, favoring VAGIFEM’s growth prospects.
• Market dynamics are shaped by competition from generics, emerging treatment modalities, and evolving safety regulations.
• Strategic pricing, product differentiation, and geographic expansion are essential to optimize VAGIFEM’s financial trajectory.
• Reimbursement policies and healthcare infrastructure significantly influence market penetration and revenue realization.
• Robust clinical evidence and safety profiles will remain critical in maintaining physician and patient trust, underpinning sales growth.

---

FAQs

1. What is VAGIFEM, and how does it compare to other vaginal estrogen therapies?
   VAGIFEM is a vaginal estrogen capsule designed for local treatment of menopausal vaginal atrophy. Its capsule formulation offers targeted delivery with a potential advantage in patient compliance compared to creams, rings, or tablets, and it is often favored for precise dosing.

2. What market segments are driving VAGIFEM's growth?
   The primary drivers include postmenopausal women experiencing vaginal atrophy, increasingly seeking localized treatment options. Healthcare providers emphasizing minimally invasive therapies and aging populations contribute to sustained demand.

3. How do regulatory challenges impact VAGIFEM’s market trajectory?
   Regulatory hurdles, including approval delays and safety assessments, can postpone market entry or expansion, affecting revenue forecasts. Conversely, positive regulatory decisions bolster confidence and market acceptance.

4. What are the main competitive threats to VAGIFEM?
   The primary threats include patent expirations leading to generics, emergence of non-hormonal alternatives, and patient preferences shifting toward newer or alternative therapies.

5. What strategies can manufacturers adopt to enhance VAGIFEM’s financial outlook?
   Focusing on clinical research, expanding geographic reach, optimizing pricing, fostering clinical awareness, and forming strategic partnerships are key strategies to sustain and grow revenues.

---

References

[1] North American Menopause Society. "Menopause Practice: A Clinical Guide." 2020.
[2] United Nations Department of Economic and Social Affairs. "World Population Prospects." 2022.
[3] MarketWatch. "Global Vaginal Estrogen Market Outlook." 2022.